| P50 | author | Víctor López-Báez | Q87890750 |
| | Mario Cozzolino | Q39187915 |
| P2093 | author name string | Jordi Bover | |
| | Andrea Galassi | |
| | Paola Ciceri | |
| | Silvia Benito | |
| | Lucía Bailone | |
| P2860 | cites work | Relationship between moderate to severe kidney disease and hip fracture in the United States | Q79150009 |
| | Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol | Q80051171 |
| | Vitamin D in chronic kidney disease: more questions than answers | Q83455140 |
| | Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study | Q84302487 |
| | Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study | Q84501495 |
| | Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 | Q85895714 |
| | Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure | Q86751763 |
| | Polio eradication: placing health before conflict | Q87494505 |
| | [Is denosmab really effective and safe in the care of CKD-MBD?] | Q88202931 |
| | Opponent's comments | Q95616300 |
| | Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis | Q24600663 |
| | European guidance for the diagnosis and management of osteoporosis in postmenopausal women | Q24612411 |
| | Bisphosphonates: mechanism of action and role in clinical practice | Q24644708 |
| | Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus | Q26996169 |
| | Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) | Q28236767 |
| | Romosozumab Treatment in Postmenopausal Women with Osteoporosis | Q28278665 |
| | Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 |
| | Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study | Q33297907 |
| | Clinical practice. Calcium supplements and fracture prevention | Q33684776 |
| | The assessment of fracture risk | Q33685092 |
| | Severely suppressed bone turnover: a potential complication of alendronate therapy | Q33983792 |
| | Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. | Q34009569 |
| | Excess mortality following hip fracture: a systematic epidemiological review | Q34017422 |
| | Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. | Q34021807 |
| | Vertebral fractures in osteoporosis: a new method for clinical assessment | Q34088476 |
| | Osteoporosis prevention, diagnosis, and therapy | Q34140339 |
| | Clinician's Guide to Prevention and Treatment of Osteoporosis | Q34250632 |
| | Bisphosphonates for osteoporosis--where do we go from here? | Q34273722 |
| | A pooled analysis of vitamin D dose requirements for fracture prevention | Q34286007 |
| | Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. | Q34354209 |
| | Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability | Q34367479 |
| | Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure | Q34393174 |
| | Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? | Q34403555 |
| | When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. | Q34453292 |
| | Adynamic bone disease: from bone to vessels in chronic kidney disease | Q34453297 |
| | Calcium plus vitamin D supplementation and the risk of fractures | Q34495055 |
| | Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial | Q34537630 |
| | Chronic kidney disease | Q34631631 |
| | Romosozumab for the treatment of osteoporosis | Q34680463 |
| | Fractures in chronic kidney disease: pursuing the best screening and management | Q38518552 |
| | Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis | Q38819059 |
| | Systematic review and meta-analysis for the association of bone mineral density and osteoporosis/osteopenia with vascular calcification in women | Q38827615 |
| | Clinical utility of anti-sclerostin antibodies | Q39003574 |
| | Safety and efficacy of denosumab in osteoporotic hemodialysed patients | Q39618928 |
| | Adynamic bone disease-bone and beyond | Q40319624 |
| | Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. | Q41191985 |
| | Uremic osteoporosis | Q42727513 |
| | Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial | Q43116648 |
| | Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series | Q43188067 |
| | Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis | Q44445112 |
| | Osteomalacia induced by vitamin D deficiency in hemodialysis patients: the crucial role of vitamin D correction | Q44542648 |
| | Incidence and risk factors for hip fractures in dialysis patients | Q44635041 |
| | Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs | Q44695650 |
| | Ten years' experience with alendronate for osteoporosis in postmenopausal women | Q44804093 |
| | Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference | Q45335311 |
| | Pro: Should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? | Q46546793 |
| | Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials | Q46809656 |
| | Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease | Q48055168 |
| | Romosozumab in postmenopausal women with low bone mineral density. | Q50481558 |
| | Assessment of the geriatric competence and perceived needs of Italian nephrologists: an internet survey. | Q50786910 |
| | Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates. | Q50960182 |
| | Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). | Q51579062 |
| | Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. | Q51789429 |
| | Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. | Q51932388 |
| | Parathyroid hormone metabolism and signaling in health and chronic kidney disease. | Q52913661 |
| | Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia | Q57215906 |
| | Epidemiology of Osteoporosis | Q57417174 |
| | Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial | Q58216569 |
| | Bone Mineral Density Predicts Fractures in Chronic Kidney Disease | Q58311152 |
| | Effects of denosumab on fracture and bone mineral density by level of kidney function | Q58970644 |
| | Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis | Q61716195 |
| | Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women | Q73150132 |
| | Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease | Q34939232 |
| | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). | Q34994912 |
| | Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy | Q35096719 |
| | Treatment of adynamic bone disease in a haemodialysis patient with teriparatide | Q35207848 |
| | Comparison of fracture risk prediction among individuals with reduced and normal kidney function. | Q35278384 |
| | Vascular calcification in patients with nondialysis CKD over 3 years | Q35278497 |
| | Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications | Q35780856 |
| | Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets | Q35962450 |
| | Assessment of fracture risk | Q35992561 |
| | Bone mineral density and fracture risk in older individuals with CKD. | Q36067875 |
| | Role of oestrogen in the regulation of bone turnover at the menarche. | Q36104307 |
| | Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). | Q36305633 |
| | Osteoporosis: a still increasing prevalence | Q36385297 |
| | A single-dose study of denosumab in patients with various degrees of renal impairment | Q36420481 |
| | The effect of raloxifene treatment in postmenopausal women with CKD. | Q36736747 |
| | Sexual function in chronic kidney disease | Q36774644 |
| | Bisphosphonate drug holiday: who, when and how long | Q36999714 |
| | Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue | Q37318510 |
| | Recombinant PTH associated with hypercalcaemia and renal failure | Q37391528 |
| | Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study | Q37426865 |
| | High rates of death and hospitalization follow bone fracture among hemodialysis patients | Q37542005 |
| | RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk | Q37625447 |
| | Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. | Q37682081 |
| | Vertebral morphometry | Q37770710 |
| | Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs | Q37951255 |
| | Osteoporosis and adynamic bone in chronic kidney disease | Q38047841 |
| | Evolving importance of kidney disease: from subspecialty to global health burden | Q38111134 |
| | Screening and treatment of osteoporosis after hip fracture: comparison of sex and race | Q38198383 |
| | Bisphosphonate-related osteonecrosis of the jaw: a review of the literature | Q38215499 |
| | Screening for vitamin D deficiency: a systematic review for the U.S. Preventive Services Task Force | Q38270839 |
| | From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. | Q38367220 |
| | Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). | Q38367232 |
| | Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline: A Randomized Clinical Trial | Q38397503 |
| | Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial | Q38400853 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| P304 | page(s) | 677-687 | |
| P577 | publication date | 2017-04-21 | |
| P1433 | published in | Journal of Nephrology | Q15765408 |
| P1476 | title | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations | |
| P478 | volume | 30 | |